Rejected Targets. If at the end of the applicable evaluation period the Evaluation License for an Approved Target is not converted into a Commercial License, or the Approved Target of any Commercial License is replaced (each such Target a “Rejected Target”), ADCT shall no longer be licensed under this Agreement with respect to such Rejected Target or any ADC Drug Reagent or Non-ADC Reagent against such Target. ADCT shall cease all work on such Rejected Target and return all materials related to such Rejected Target provided by MedImmune to MedImmune. No Rejected Target may be reselected for an Evaluation License or a Commercial License.
Appears in 4 contracts
Samples: License Agreement (ADC Therapeutics SA), License Agreement (ADC Therapeutics SA), License Agreement (ADC Therapeutics SA)
